arrow
J

Ji-Youn Han

National Cancer Center
H指数:69
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy ( ATTLAS , KCSG ‐ LU19 ‐04) in EGFR / ALK ‐Mutated Non–Small‐Cell Lung Cancer

来自阿替利珠单抗联合贝伐珠单抗和化疗(<scp>ATTLAS</scp>,<scp>KCSG</scp>‐<scp>LU19</scp>‐04)治疗<scp>EGFR</scp>/<scp>ALK</scp>突变非小细胞肺癌的III期研究生活质量结果

2026-11-160
PRE
Landscape of cancer genomics and precision oncology in Japan, South Korea, China, and Australia

日本、韩国、中国和澳大利亚癌症基因组学与精准肿瘤学的现状

2026-09-100
OAAI
Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

作者勘误:靶向SEZ6的抗体药物偶联物ABBV-706在晚期小细胞肺癌和实体瘤中的研究:一项1期临床试验

2026-06-290
OAAI
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

靶向SEZ6抗体偶联药物ABBV-706在晚期小细胞肺癌和实体瘤中的I期临床试验

2026-06-010
OAAI
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

奥罗玛西布(olomorasib)对KRAS G12C突变型晚期实体瘤的泛瘤活性:一项首次人体研究

2026-03-120
OAAI
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial
2025-12-010
PRE
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC

奥罗莫西布与帕博利珠单抗联合治疗KRAS G12C突变型晚期非小细胞肺癌的疗效与安全性

2025-11-290
PRE
Central nervous system outcomes of lazertinib treatment in EGFR-mutated advanced NSCLC: Pooled analysis from LASER201 and LASER301

拉泽替尼治疗EGFR突变晚期NSCLC的神经系统结局:LASER201和LASER301的合并分析

2025-09-010
PREAI
Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor–tyrosine kinase inhibitor resistance subclones

对难治性肺癌进行纵向药基因组学分析,以识别表皮生长因子受体–酪氨酸激酶抑制剂耐药亚克隆的治疗候选物

2025-07-040
OA
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

Amivantamab在晚期NSCLC和MET外显子14跳跃突变参与者中的应用: CHRYSALIS研究的最终结果

2025-05-160
PREAI
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial

一项关于阿替利珠单抗、贝伐珠单抗和化疗在获得性耐药的EGFR突变非小细胞肺癌中的随机非对照II期研究——ETOP 15-19 ABC-lung试验

2025-04-010
PRE
TROPION-Lung07: Phase III study of Dato-DXd plus pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer

TROPION-Lung07: dato-dxd联合pembrolizumab ± 铂类化疗作为1L治疗晚期非小细胞肺癌的III期研究

2024-10-291
OAAI
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study

1/2期LASER201研究中使用拉泽替尼治疗的EGFR T790M-positive晚期非小细胞肺癌患者的更新的总生存期和ctDNA分析

2024-10-080
OAAI
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024-09-090
PRE
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
2024-07-010
OA